These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

313 related items for PubMed ID: 29406430

  • 1. Brief Report: Abacavir/Lamivudine and Tenofovir/Emtricitabine in Pregnant Women With HIV: Laboratory and Clinical Outcomes in an Observational National Study.
    Floridia M, Pinnetti C, Ravizza M, Masuelli G, Personeni C, Sansone M, Degli Antoni A, Guaraldi G, Spinillo A, Tassis B, Dalzero S, Liuzzi G, Tamburrini E.
    J Acquir Immune Defic Syndr; 2018 May 01; 78(1):99-104. PubMed ID: 29406430
    [Abstract] [Full Text] [Related]

  • 2. SWIFT: prospective 48-week study to evaluate efficacy and safety of switching to emtricitabine/tenofovir from lamivudine/abacavir in virologically suppressed HIV-1 infected patients on a boosted protease inhibitor containing antiretroviral regimen.
    Campo R, DeJesus E, Bredeek UF, Henry K, Khanlou H, Logue K, Brinson C, Benson P, Dau L, Wang H, White K, Flaherty J, Fralich T, Guyer B, Piontkowsky D.
    Clin Infect Dis; 2013 Jun 01; 56(11):1637-45. PubMed ID: 23362296
    [Abstract] [Full Text] [Related]

  • 3. Randomized, double-blind, placebo-matched, multicenter trial of abacavir/lamivudine or tenofovir/emtricitabine with lopinavir/ritonavir for initial HIV treatment.
    Smith KY, Patel P, Fine D, Bellos N, Sloan L, Lackey P, Kumar PN, Sutherland-Phillips DH, Vavro C, Yau L, Wannamaker P, Shaefer MS, HEAT Study Team.
    AIDS; 2009 Jul 31; 23(12):1547-56. PubMed ID: 19542866
    [Abstract] [Full Text] [Related]

  • 4. Switching to tenofovir/emtricitabine from abacavir/lamivudine in HIV-infected adults with raised cholesterol: effect on lipid profiles.
    Behrens G, Maserati R, Rieger A, Domingo P, Abel F, Wang H, Pearce G.
    Antivir Ther; 2012 Jul 31; 17(6):1011-20. PubMed ID: 22910324
    [Abstract] [Full Text] [Related]

  • 5. Cost-effectiveness of DTG + ABC/3TC versus EFV/TDF/FTC for first-line treatment of HIV-1 in the United States.
    Peng S, Tafazzoli A, Dorman E, Rosenblatt L, Villasis-Keever A, Sorensen S.
    J Med Econ; 2015 Jul 31; 18(10):763-76. PubMed ID: 25934146
    [Abstract] [Full Text] [Related]

  • 6. Birth Outcomes for Pregnant Women with HIV Using Tenofovir-Emtricitabine.
    Rough K, Seage GR, Williams PL, Hernandez-Diaz S, Huo Y, Chadwick EG, Currier JS, Hoffman RM, Barr E, Shapiro DE, Patel K, PHACS and the IMPAACT P1025 Study Teams.
    N Engl J Med; 2018 Apr 26; 378(17):1593-1603. PubMed ID: 29694825
    [Abstract] [Full Text] [Related]

  • 7. A randomized comparative trial of continued abacavir/lamivudine plus efavirenz or replacement with efavirenz/emtricitabine/tenofovir DF in hypercholesterolemic HIV-1 infected individuals.
    Moyle GJ, Orkin C, Fisher M, Dhar J, Anderson J, Wilkins E, Ewan J, Ebrahimi R, Wang H, ROCKET 1 (Randomized Open Label Switch for Cholesterol Elevation on Kivexa Evaluation Trial) Study Group.
    PLoS One; 2015 Apr 26; 10(2):e0116297. PubMed ID: 25658097
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. The ASSURE study: HIV-1 suppression is maintained with bone and renal biomarker improvement 48 weeks after ritonavir discontinuation and randomized switch to abacavir/lamivudine + atazanavir.
    Wohl DA, Bhatti L, Small CB, Edelstein H, Zhao HH, Margolis DA, DeJesus E, Weinberg WG, Ross LL, Shaefer MS.
    HIV Med; 2016 Feb 26; 17(2):106-17. PubMed ID: 26176344
    [Abstract] [Full Text] [Related]

  • 10. Cost-utility analysis of the fixed-dose combination of dolutegravir/abacavir/lamivudine as initial treatment of HIV+ patients in Spain.
    Moreno Guillen S, Losa García JE, Berenguer Berenguer J, Martínez Sesmero JM, Cenoz Gomis S, Graefenhain R, Lopez Sanchez-Cambronero D, Parrondo Garcia FJ.
    Farm Hosp; 2017 Sep 01; 41(5):601-610. PubMed ID: 28847249
    [Abstract] [Full Text] [Related]

  • 11. Bone mineral density and fractures in antiretroviral-naive persons randomized to receive abacavir-lamivudine or tenofovir disoproxil fumarate-emtricitabine along with efavirenz or atazanavir-ritonavir: Aids Clinical Trials Group A5224s, a substudy of ACTG A5202.
    McComsey GA, Kitch D, Daar ES, Tierney C, Jahed NC, Tebas P, Myers L, Melbourne K, Ha B, Sax PE.
    J Infect Dis; 2011 Jun 15; 203(12):1791-801. PubMed ID: 21606537
    [Abstract] [Full Text] [Related]

  • 12. Cost-effectiveness analysis of tenofovir/emtricitabine and abacavir/lamivudine in combination with efavirenz or atazanavir/ritonavir for treatment-naïve adults with HIV-1 infection in the UK, based on the AIDS Clinical Trials Group 5202 clinical trial.
    Wilkins E, Fisher M, Brogan AJ, Talbird SE, La EM.
    HIV Med; 2016 Aug 15; 17(7):505-15. PubMed ID: 26663715
    [Abstract] [Full Text] [Related]

  • 13. Simplification of antiretroviral therapy with tenofovir-emtricitabine or abacavir-Lamivudine: a randomized, 96-week trial.
    Martin A, Bloch M, Amin J, Baker D, Cooper DA, Emery S, Carr A.
    Clin Infect Dis; 2009 Nov 15; 49(10):1591-601. PubMed ID: 19842973
    [Abstract] [Full Text] [Related]

  • 14. 96-Week results of abacavir/lamivudine versus tenofovir/emtricitabine, plus efavirenz, in antiretroviral-naive, HIV-1-infected adults: ASSERT study.
    Moyle GJ, Stellbrink HJ, Compston J, Orkin C, Arribas JR, Domingo P, Granier C, Pearce H, Sedani S, Gartland M, ASSERT Team.
    Antivir Ther; 2013 Nov 15; 18(7):905-13. PubMed ID: 23899468
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Evaluation of the Lipid Concentrations after Switching from Antiretroviral Drug Tenofovir Disoproxil Fumarate/Emtricitabine to Abacavir Sulfate/Lamivudine in Virologically-suppressed Human Immunodeficiency Virus-infected Patients.
    Arae H, Tateyama M, Nakamura H, Tasato D, Kami K, Miyagi K, Maeda S, Uehara H, Moromi M, Nakamura K, Fujita J.
    Intern Med; 2016 Nov 15; 55(23):3435-3440. PubMed ID: 27904105
    [Abstract] [Full Text] [Related]

  • 17. Abacavir/lamivudine versus tenofovir DF/emtricitabine as part of combination regimens for initial treatment of HIV: final results.
    Sax PE, Tierney C, Collier AC, Daar ES, Mollan K, Budhathoki C, Godfrey C, Jahed NC, Myers L, Katzenstein D, Farajallah A, Rooney JF, Ha B, Woodward WC, Feinberg J, Tashima K, Murphy RL, Fischl MA, AIDS Clinical Trials Group Study A5202 Team.
    J Infect Dis; 2011 Oct 15; 204(8):1191-201. PubMed ID: 21917892
    [Abstract] [Full Text] [Related]

  • 18. Comparative risk of failure of ABC/3TC or TDF/FTC based first-line regimens in patients with a high viral load.
    Flandre P, Pugliese P, Allavena C, Katlama C, Cotte L, Cheret A, Cabié A, Rey D, Chirouze C, Bani-Sadr F, Cuzin L, Dat'AIDS Study group.
    HIV Med; 2016 May 15; 17(5):380-4. PubMed ID: 27093565
    [Abstract] [Full Text] [Related]

  • 19. Effects of nucleoside reverse transcriptase inhibitor backbone on the efficacy of first-line boosted highly active antiretroviral therapy based on protease inhibitors: meta-regression analysis of 12 clinical trials in 5168 patients.
    Hill A, Sawyer W.
    HIV Med; 2009 Oct 15; 10(9):527-35. PubMed ID: 19785663
    [Abstract] [Full Text] [Related]

  • 20. Changes in fat mitochondrial DNA and function in subjects randomized to abacavir-lamivudine or tenofovir DF-emtricitabine with atazanavir-ritonavir or efavirenz: AIDS Clinical Trials Group study A5224s, substudy of A5202.
    McComsey GA, Daar ES, O'Riordan M, Collier AC, Kosmiski L, Santana JL, Fichtenbaum CJ, Fink H, Sax PE, Libutti DE, Gerschenson M.
    J Infect Dis; 2013 Feb 15; 207(4):604-11. PubMed ID: 23204164
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.